Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SAKAR.NS
BuyPremium GrowerSakar Healthcare Limited · Healthcare · India · $268M · Avg Vol: $2M/d
79
StockRankGet insider-trade alerts
Q
64
V
17
M
93
P/E (TTM)
83.6x
ROE
9.4%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India.
FINANCIAL SUMMARY (INR)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.3B | 1.5B | 1.8B | 2.5B | 23.6% | 2.7B | 3.4B | 4.8B | 38.2% |
| EPS (INR) | 10.09 | 6.86 | 5.69 | 8.03 | 13.70 | 7.9% | 13.78 | 23.00 | 40.90 | 72.8% |
| Shares | — | 19.0M | 21.7M | 21.9M | 22.2M | +16.9% | 21.9M | — | — | — |
| Debt | — | 1.2B | 793.5M | 863.7M | 705.3M | -16.0% | 705.3M | — | — | — |
| Equity | — | 1.7B | 2.6B | 2.9B | 3.2B | 23.2% | — | — | — | — |
| Op CF | — | 333.4M | 244.7M | 340.3M | 492.6M | 13.9% | 492.6M | — | — | — |
| Inv CF | — | -743.8M | -515.4M | -307.1M | -283.5M | — | — | — | — | — |
| Fin CF | — | 411.0M | 274.4M | -34.8M | -209.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+35.6%
SMA 50SMA 200
Close
$12.12
RSI (14)
83.2
52W High
$12.73
From 52W High
1.0%
SCORE BREAKDOWN
Quality
64
ROIC
12.8%78.2
ROE
9.4%68.5
GP/Assets
29.7%63.0
Op. Margin
20.2%83.4
FCF/Assets
4.3%67.2
Piotroski
668.8
Int. Cover
6.1x54.2
D/E Ratio
0.22x48.6
Current Ratio
1.28x19.5
Value
17
P/E (TTM)
83.6x11.2
EV/EBITDA
34.2x18.7
P/FCF
122.0x14.0
P/B
7.9x16.0
P/S
9.3x27.1
Div Yield
—N/A
Momentum
93
52W High %
95%93.7
RS 6M
118%97.6
SMA 50/200
1.40x96.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+197%87.1
Q Growth
120%85.9
FUNDAMENTALS
Market Cap
$268M
P/E (Forward)
28.2x
Gross Margin
52.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SAKAR.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SAKAR.NS | Sakar Healthcare Limited(you) | $268M | 79 | Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| HIKAL.NS | Hikal Limited | $320M | 75 | Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| BETA.NS | Beta Drugs Limited | $228M | 72 | Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| FDC.NS | FDC Limited | $594M | 76 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%